Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02927262
Status:
COMPLETED
Last Update Posted:
2024-03-15
First Post:
2016-10-05
Brief Title:
A Study of ASP2215 Gilteritinib Administered as Maintenance Therapy Following InductionConsolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 FLT3ITD Acute Myeloid Leukemia AML in First Complete Remission
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Acute Myeloid Leukemia AML |
| Acute Myeloid Leukemia With FMS-like Tyrosine Kinase FLT3 Internal Tandem Duplication ITD Mutation |